Latest News and Press Releases
Want to stay updated on the latest news?
-
Webinar to be held on December 22nd @ 12pm EST NLC Pharma and Todos agree to extend closing date for formation of 3CL Sciences to December 31, 2021 while the companies complete legal due diligence ...
-
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Dec. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions...
-
New York, NY, and Tel Aviv, ISRAEL, Dec. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today...
-
Combined testing from two contracts averages 1,000 PCR samples per dayTesting potential for the two contracts could ramp up to 5,000 PCR samples per day New York, NY, Alpharetta, GA and Tel...
-
New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today...
-
Dr. Jules Mitchel now leading preparation for data lock and statistical analysisBusiness update call Today at 4:30PM EST New York, NY, and Tel Aviv, ISRAEL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- via...
-
New York, NY, and Tel Aviv, ISRAEL, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related...
-
Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant-agnostic COVID-19 antivirals such as Tollovir that utilize the 3CL protease related IPDr. Dorit...
-
Provista to also utilize Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant New York, NY, and Tel Aviv, ISRAEL, Nov. 30, 2021 (GLOBE...
-
Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant-agnostic COVID-19 antivirals such as Tollovir that utilize the 3CL protease related IP Dr....